Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Byetta exenatide LAR endocrine data

In a 30-week, open-label trial in 295 patients, once-weekly injections of exenatide LAR met the primary endpoint of non-inferiority

Read the full 191 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE